company background image
GRTX logo

Galera Therapeutics NasdaqGM:GRTX Stock Report

Last Price

US$0.15

Market Cap

US$8.3m

7D

-36.7%

1Y

-94.3%

Updated

27 Mar, 2024

Data

Company Financials

Galera Therapeutics, Inc.

NasdaqGM:GRTX Stock Report

Market Cap: US$8.3m

GRTX Stock Overview

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer.

GRTX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Galera Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Galera Therapeutics
Historical stock prices
Current Share PriceUS$0.15
52 Week HighUS$3.59
52 Week LowUS$0.085
Beta2.23
1 Month Change-20.05%
3 Month Change7.34%
1 Year Change-94.27%
3 Year Change-98.26%
5 Year Changen/a
Change since IPO-98.72%

Recent News & Updates

Recent updates

Galera Therapeutics (NASDAQ:GRTX) Will Have To Spend Its Cash Wisely

Feb 15
Galera Therapeutics (NASDAQ:GRTX) Will Have To Spend Its Cash Wisely

Galera Therapeutics (NASDAQ:GRTX) Will Have To Spend Its Cash Wisely

Oct 25
Galera Therapeutics (NASDAQ:GRTX) Will Have To Spend Its Cash Wisely

Galera Therapeutics appoints chief medical officer

Sep 01

Galera down ~8% after phase 1 data for non-small cell lung cancer combination treatment

Jun 29

Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky

Jun 15
Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky

Is Galera Therapeutics Stock A Buy, Sell, Or Hold? Several Catalysts To Watch In 2022

Mar 23

Here's Why We're A Bit Worried About Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation

Feb 24
Here's Why We're A Bit Worried About Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation

Galera Therapeutics: Trial Reversal Did Not Take The Stock Higher

Dec 24

Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky

Nov 04
Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky

Will Galera Therapeutics (NASDAQ:GRTX) Spend Its Cash Wisely?

Aug 05
Will Galera Therapeutics (NASDAQ:GRTX) Spend Its Cash Wisely?

Here's Why We're Watching Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation

Feb 17
Here's Why We're Watching Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation

Galera Therapeutics EPS beats by $0.08

Nov 10

Shareholder Returns

GRTXUS BiotechsUS Market
7D-36.7%0.9%0.4%
1Y-94.3%10.3%28.8%

Return vs Industry: GRTX underperformed the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: GRTX underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is GRTX's price volatile compared to industry and market?
GRTX volatility
GRTX Average Weekly Movement20.1%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: GRTX's share price has been volatile over the past 3 months.

Volatility Over Time: GRTX's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201231J. Sorensenhttps://www.galeratx.com

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company’s lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer.

Galera Therapeutics, Inc. Fundamentals Summary

How do Galera Therapeutics's earnings and revenue compare to its market cap?
GRTX fundamental statistics
Market capUS$8.35m
Earnings (TTM)-US$69.68m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GRTX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$69.68m
Earnings-US$69.68m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.28
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio-118.8%

How did GRTX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.